Proximal inhibition of p38 MAPK stress signaling prevents distal axonopathy

Neurobiology of Disease

Volumn 59, Issue , 2013, Pages 26-37

  Dapper, Jason D ^a   Crish, Samuel D ^b   Pang, Iok Hou ^c   Calkins, David J ^a,d  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Axonopathy; Glaucoma; Heat shock protein; Neurodegeneration; P38 MAPK; Retinal ganglion cell

Indexed keywords

1 [4 [3 (4 FLUOROPHENYL) 1H PYRROLO[3,2 B]PYRIDIN 2 YL]PYRIDIN 2 YL AMINO]PROPAN 2 OL; HEAT SHOCK PROTEIN 27; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; RO 3206145; TAU PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE CONTROL; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME LOCALIZATION; INTRAOCULAR PRESSURE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; OPTIC NERVE DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; RETINA GANGLION CELL; SIGNAL TRANSDUCTION;

ACTIVATING TRANSCRIPTION FACTOR 2; APOPTOSIS SIGNAL-REGULATING KINASE 1; ASK1; ATF2; AXONOPATHY; CERULOPLASMIN; CHOLERA TOXIN SUBUNIT Β; CP; CTB; GFAP; GLAUCOMA; GLIAL ACIDIC FIBRILLARY PROTEIN; HEAT SHOCK PROTEIN; HSP27, HSP60; INTRAOCULAR PRESSURE; IOP; MAPK; MITOGEN-ACTIVATED PROTEIN KINASE; NEURODEGENERATION; P38 MAPK; RETINAL GANGLION CELL; RGC; RO3206145 (1-{4-[3-(4-FLUORO-PHENYL)-1H-PYRROLO[3,2-B]PYRIDIN-2-YL]-PYRIDIN-2-YLAMINO}-PROPAN-2-OL), HEAT-SHOCK PROTEIN 27 AND 60; SC; SUPERIOR COLLICULUS; TIMP3; TISSUE INHIBITOR OF METALLOPROTEINASES-3; Α-DETUB; Α-DETYROSINATED TUBULIN;

ACTIVATING TRANSCRIPTION FACTOR 2; ANIMALS; AXONS; CHAPERONIN 60; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; IMIDAZOLES; INTRAOCULAR PRESSURE; MICE; NERVE TISSUE PROTEINS; OCULAR HYPERTENSION; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; RATS; RETINA; RETINAL DEGENERATION; RETINAL GANGLION CELLS; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 84881116180     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.07.001     Document Type: Article

References (67)

1. Ackerley S., Grierson A.J., Banner S., Perkinton M.S., Brownlees J., Byers H.L., Ward M., Thornhill P., Hussain K., Waby J.S., Anderton B.H., Cooper J.D., Dingwall C., Leigh P.N., Shaw C.E., Miller C.C. p38alpha stress-activated protein kinase phosphorylates neurofilaments and is associated with neurofilament pathology in amyotrophic lateral sclerosis. Mol. Cell. Neurosci. 2004, 26(2):354-364. (PMID: 15207859).
2. Almasieh M., Wilson A.M., Morquette B., Cueva Vargas J.L., Di Polo A. The molecular basis of retinal ganglion cell death in glaucoma. Prog. Retin. Eye Res. 2012, 31(2):152-181. (PMID: 22155051).
3. Ashwell J.D. The many paths to p38 mitogen-activated protein kinase activation in the immune system. Nat. Rev. Immunol. 2006, 6(7):532-540.
4. Barone F.C., Irving E.A., Ray A.M., Lee J.C., Kassis S., Kumar S., Badger A.M., Legos J.J., Erhardt J.A., Ohlstein E.H., Hunter A.J., Harrison D.C., Phipott K., Smith B.R., Adams J.L., Parsons A.A. Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia. Med. Res. Rev. 2001, 21(2):129-145. (PMID: 11223862).
5. Bendotti C., Bao Cutrona M., Cheroni C., Grignaschi G., Lo Coco D., Peviani M., Tortarolo M., Veglianese P., Zennaro E. Inter- and intracellular signaling in amyotrophic lateral sclerosis: role of p38 mitogen-activated protein kinase. Neurodegener Dis 2005, 2(3-4):128-134.
6. Bosco A., Inman D.M., Steele M.R., Wu G., Soto I., Marsh-Armstrong N., Hubbard W.C., Calkins D.J., Horner P.J., Vetter M.L. Reduced retina microglial activation and improved optic nerve integrity with minocycline treatment in the DBA/2J mouse model of glaucoma. Invest. Ophthalmol. Vis. Sci. 2008, 49(4):1437-1446. (Apr).
7. Buckingham B.P., Inman D.M., Lambert W., Oglesby E., Calkins D.J., Steele M.R., Vetter M.L., Marsh-Armstrong N., Horner P.J. Progressive ganglion cell degeneration precedes neuronal loss in a mouse model of glaucoma. J. Neurosci. 2008, 28:2735-2744.
8. Calkins D.J. Critical pathogenic events underlying progression of neurodegeneration in glaucoma. Prog. Retin. Eye Res. 2012, 31(6):702-719.
9. Chen H., Wei X., Cho K.S., Chen G., Sappington R., Calkins D.J., Chen D.F. Optic neuropathy due to microbead-induced elevated intraocular pressure in the mouse. Invest. Ophthalmol. Vis. Sci. 2011, 52(1):36-44. (PMID: 20702815).
10. Coleman M.P. Axon degeneration mechanisms: commonality amid diversity. Nat. Rev. Neurosci. 2005, 11:889-898.
11. Coleman M.P., Perry V.H. Axon pathology in neurological disease: a neglected therapeutic target. Trends Neurosci. 2002, 25(10):532-537.
12. Cone F.E., Gelman S.E., Son J.L., Pease M.E., Quigley H.A. Differential susceptibility to experimental glaucoma among 3 mouse strains using bead and viscoelastic injection. Exp. Eye Res. 2010, 91(3):415-424. (PMID: 20599961).
13. Corrêa S.A., Eales K.L. The Role of p38 MAPK and its substrates in neuronal plasticity and deurodegenerative disease. J. Signal. Transduct. 2012, 2012:649079.
14. Crish S.D., Sappington R.M., Inman D.M., Horner P.J., Calkins D.J. Distal axonopathy with structural persistence in glaucomatous neurodegeneration. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(11):5196-5201. (PMID: 20194762).
15. Crish S.D., Dapper J.D., MacNamee S.E., Balaram P., Sidorova T.N., Lambert W.S., Calkins D.J. Failure of axonal transport induces a spatially coincident increase in astrocyte BDNF prior to synapse loss in a central target. Neuroscience 2013, 229:55-70. (Jan 15).
16. Cuadrado A., Nebreda A.R. Mechanisms and functions of p38 MAPK signaling. Biochem. J. 2010, 429(3):403-417. (PMID: 20626350).
17. Ding H., Gabali A.M., Jenson S.D., Lim M.S., Elenitoba-Johnson K.S. P38 mitogen activated protein kinase expression and regulation by interleukin-4 in human B cell non-Hodgkin lymphomas. J. Hematop. 2009, 2(4):195-204. (Oct 21, PMID: 20309428).
18. El-Remessy A.B., Tang Y., Zhu G., Matragoon S., Khalifa Y., Liu E.K., Liu J.Y., Hanson E., Mian S., Fatteh N., Liou G.I. Neuroprotective effects of cannabidiol in endotoxin-induced uveitis: critical role of p38 MAPK activation. Mol. Vis. 2008, 14:2190-2203.
19. Ferrer I. Stress kinases involved in tau phosphorylation in Alzheimer's disease, tauopathies and APP transgenic mice. Neurotox. Res. 2004, 6(6):469-475. (PMID: 15658002).
20. Ferrer I., Gomez-Isla T., Puig B., Freixes M., Ribe E., Dalfo E., Avila J. Current advances in different kinases involved in tau phosphorylation, and implication in Alzheimer's disease and tauopathies. Curr. Alzheimer Res. 2005, 2(1):3-18. (PMID: 15977985).
21. Gasparini L., Crowther R.A., Martin K.R., Berg N., Coleman M., Goedert M., Spillantini M.G. Tau inclusions in retinal ganglion cells of human P301S tau transgenic mice: effects on axonal viability. Neurobiol. Aging 2011, 32(3):419-433. (PMID: 19356824).
22. Gupta N., Fong J., Ang L.C., Yucel Y.H. Retinal tau pathology in human glaucomas. Can. J. Ophthalmol. 2008, 43(1):53-60. (PMID: 18219347).
23. Hanna M.C., Calkins D.J. Expression and sequences of genes encoding glutamate receptors and transporters in primate retina determined using 3'-end amplification polymerase chain reaction. Mol. Vis. 2006, 12:961-976. (PMID: 16943768).
24. Harada C., Nakamura K., Namekata K., Okumura A., Mitamura Y., Iizuka Y., Kashiwagi K., Yoshida K., Ohno S., Matsuzawa A., Tanaka K., Ichijo H., Harada T. Role of apoptosis signal-regulating kinase 1 in stress-induced neural cell apoptosis in vivo. Am. J. Pathol. 2006, 168(1):261-269. (Jan, PMCID: PMC1592659).
25. Harada C., Namekata K., Guo X., Yoshida H., Mitamura Y., Matsumoto Y., Tanaka K., Ichijo H., Harada T. ASK1 deficiency attenuates neural cell death in GLAST-deficient mice, a model of normal tension glaucoma. Cell Death Differ. 2010, 17(11):1751-1759. (PMID: 20489729).
26. Harper S.J., LoGrasso P. Signalling for survival and death in neurons: the role of stress-activated kinases, JNK and p38. Cell. Signal. 2001, 13(5):299-310. (PMID: 11369511).
27. Hensley K., Floyd R.A., Zheng N.Y., Nael R., Robinson K.A., Nguyen X., Pye Q.N., Stewart C.A., Geddes J., Markesbery W.R., Patel E., Johnson G.V., Bing G. p38 kinase is activated in the Alzheimer's disease brain. J. Neurochem. 1999, 72(5):2053-2058. (PMID: 10217284).
28. Howell G.R., Soto I., Zhu X., Ryan M., Macalinao D.G., Sousa G.L., Caddle L.B., Macnicoll K.H., Barbay J.M., Porciatti V., Anderson M.G., Smith R.S., Clark A.F., Libby R.T., John S.W. Radiation treatment inhibits monocyte entry into the optic nerve head and prevents neuronal damage in a mouse model of glaucoma. J. Clin. Invest. 2012, 122:1246-1261. (PMID: 22426214).
29. Hsieh C.C., Papaconstantinou J. Thioredoxin-ASK1 complex levels regulate ROS-mediated p38 MAPK pathway activity in livers of aged and long-lived Snell dwarf mice. FASEB J. 2006, 20(2):259-268. (PMID: 16449798).
30. Huang W., Fileta J.B., Filippopoulos T., Ray A., Dobberfuhl A., Grosskreutz C.L. Hsp27 phosphorylation in experimental glaucoma. Invest. Ophthalmol. Vis. Sci. 2007, 48(9):4129-4135. (PMID: 17724197).
31. Inman D.M., Sappington R.S., Horner P.J., Calkins D.J. Quantitative correlation of optic nerve pathology with ocular pressure and corneal thickness in the DBA/2 mouse model of glaucoma. Invest. Ophthalmol. Vis. Sci. 2006, 47:986-996. (PMID: 16505033).
32. Kabuyama Y., Homma M.K., Kurosaki T., Homma Y. Early signaling events induced by 280-nm UV irradiation. Eur. J. Biochem. 2002, 269(2):664-670. (Jan).
33. Kikuchi M., Tenneti L., Lipton S.A. Role of p38 mitogen-activated protein kinase in axotomy-induced apoptosis of rat retinal ganglion cells. J. Neurosci. 2000, 20(13):5037-5044. (PMID: 10864961).
34. Kostenko S., Moens U. Heat shock protein 27 phosphorylation: kinases, phosphatases, functions and pathology. Cell. Mol. Life Sci. 2009, 66(20):3289-3307. (PMID: 19593530).
35. Lambert W.S., Ruiz L., Crish S.D., Wheeler L.A., Calkins D.J. Brimonidine prevents axonal and somatic degeneration of retinal ganglion cell neurons. Mol. Neurodegener. 2011, 6(1):4. (PMID: 21232114).
36. Lee K.H., Yun S.J., Nam K.N., Gho Y.S., Lee E.H. Activation of microglial cells by ceruloplasmin. Brain Res. 2007, 1171:1-8. (PMID 17727827).
37. Legos J.J., Erhardt J.A., White R.F., Lenhard S.C., Chandra S., Parsons A.A., Tuma R.F., Barone F.C. SB 239063, a novel p38 inhibitor, attenuates early neuronal injury following ischemia. Brain Res. 2001, 892(1):70-77. (PMID: 11172750).
38. Levkovitch-Verbin H., Harizman N., Dardik R., Nisgav Y., Vander S., Melamed S. Regulation of cell death and survival pathways in experimental glaucoma. Exp. Eye Res. 2007, 85(2):250-258. (PMID: 17586494).
39. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25(4):402-408. (PMID: 11846609).
40. Malemud C.J. Inhibitors of stress-activated protein/mitogen-activated protein kinase pathways. Curr. Opin. Pharmacol. 2007, 7(3):339-343. (PMID: 17398158).
41. Manabe S., Lipton S.A. Divergent NMDA signals leading to proapoptotic and antiapoptotic pathways in the rat retina. Invest. Ophthalmol. Vis. Sci. 2003, 44(1):385-392. (PMID: 12506100).
42. Mielke K., Herdegen T. JNK and p38 stress kinases-degenerative effectors of signal-transduction-cascades in the nervous system. Prog. Neurobiol. 2000, 61(1):45-60. (PMID: 10759064).
43. Munemasa Y., Ohtani-Kaneko R., Kitaoka Y., Kuribayashi K., Isenoumi K., Kogo J., Yamashita K., Kumai T., Kobayashi S., Hirata K., Ueno S. Contribution of mitogen-activated protein kinases to NMDA-induced neurotoxicity in the rat retina. Brain Res. 2005, 1044(2):227-240. (PMID: 15885221).
44. Munoz L., Ammit A.J. Targeting p38 MAPK pathway for the treatment of Alzheimer's disease. Neuropharmacology 2010, 58(3):561-568. (PMID: 19951717).
45. Munoz L., Ralay Ranaivo H., Roy S.M., Hu W., Craft J.M., McNamara L.K., Chico L.W., Van Eldik L.J., Watternson D.M. A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. J. Neuroinflammation 2007, 4:21. (PMID: 17784957).
46. Nguyen D., Alavi M.V., Kim K.Y., Kang T., Scott R.T., Noh Y.H., Lindsey J.D., Wissinger B., Ellisman M.H., Weinreb R.N., Perkins G.A., Ju W.K. A new vicious cycle involving glutamate excitotoxicity, oxidative stress and mitochondrial dynamics. Cell Death Dis. 2011, 2:e240.
47. Nickells R.W., Howell G.R., Soto I., John S.W. Under pressure: cellular and molecular responses during glaucoma, a common neurodegeneration with axonopathy. Annu. Rev. Neurosci. 2012, 35:153-179.
48. Nucci C., Martucci A., Martorana A., Sancesario G.M., Cerulli L. Glaucoma progression associated with altered cerebral spinal fluid levels of amyloid-beta and tau proteins. Clin. Exp. Ophthalmol. 2011, 39(3):279-281. (PMID: 20973903).
49. Osborne N.N. Mitochondria: Their role in ganglion cell death and survival in primary open angle glaucoma. Exp. Eye Res. 2010, 90(6):750-757.
50. Peifer C., Wagner G., Laufer S. New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase. Curr. Top. Med. Chem. 2006, 6(2):113-149. (PMID: 16454763).
51. Quigley H.A., Broman A.T. The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol. 2006, 90(3):262-267. (PMID: 16488940).
52. Reynolds C.H., Betts J.C., Blackstock W.P., Nebreda A.R., Anderton B.H. Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3beta. J. Neurochem. 2000, 74(4):1587-1595. (PMID: 10737616).
53. Ronkina N., Kotlyarov A., Dittrich-Breiholz O., Kracht M., Hitti E., Milarski K., Askew R., Marusic S., Lin L.L., Gaestel M., Telliez J.B. The mitogen-activated protein kinase (MAPK)-activated protein kinases MK2 and MK3 cooperate in stimulation of tumor necrosis factor biosynthesis and stabilization of p38 MAPK. Mol. Cell. Biol. 2007, 27(1):170-181. (PMID: 17030606).
54. Sappington R.M., Sidorova T., Long D.J., Calkins D.J. TRPV1: contribution to retinal ganglion cell apoptosis and increased intracellular Ca2+ with exposure to hydrostatic pressure. Invest. Ophthalmol. Vis. Sci. 2009, 50:717-728. (PMID: 18952924).
55. Sappington R.M., Carlson B.J., Crish S.D., Calkins D.J. The microbead occlusion model: a paradigm for induced ocular hypertension in rats and mice. Invest. Ophthalmol. Vis. Sci. 2010, 51(1):207-216. (PMID: 19850836).
56. Shih G.C., Calkins D.J. Secondary neuroprotective effects of hypotensive drugs and potential mechanisms of action. Expert Rev. Ophthalmol. 2012, 7(2):161-175. (PMID: 22737176).
57. Stasi K., Nagel D., Yang X., Ren L., Mittag T., Danias J. Ceruloplasmin upregulation in retina of murine and human glaucomatous eyes. Invest. Ophthalmol. Vis. Sci. 2007, 48(2):727-732. (PMID: 17251471).
58. Sun A., Liu M., Nguyen X.V., Bing G. p38 MAP kinase is activated at early stages in Alzheimer's disease brain. Exp. Neurol. 2003, 183(2):394-405. (PMID: 14552880).
59. Sun H., Wang Y., Pang I.H., Shen J., Tang X., Li Y., Liu C., Li B. Protective effect of a JNK inhibitor against retinal ganglion cell loss induced by acute moderate ocular hypertension. Mol. Vis. 2011, 17:864-875. (PMID: 21527996).
60. Tezel G., Chauhan B.C., LeBlanc R.P., Wax M.B. Immunohistochemical assessment of the glial mitogen-activated protein kinase activation in glaucoma. Invest. Ophthalmol. Vis. Sci. 2003, 44(7):3025-3033. (PMID: 12824248).
61. Trejo A., Arzeno H., Browner M., Chanda S., Cheng S., Comer D.D., Dalrymple S.A., Dunten P., Lafarque J., Lovejoy B., Freire-Moar J., Lim J., Mcintosh J., Miller J., Papp E., Reuter D., Roberts R., Sanpablo F., Saunders J., Song K., Villasenor A., Warren S.D., Welch M., Weller P., Whiteley P.E., Zeng L., Goldstein D.M. Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinase. J. Med. Chem. 2003, 46(22):4702-4713. (PMID: 14561090).
62. Wagner G., Laufer S. Small molecular anti-cytokine agents. Med. Res. Rev. 2006, 26(1):1-62. (Jan).
63. Wax M.B., Tezel G., Yang J., Peng G., Patil R.V., Agarwal N., Sappington R.M., Calkins D.J. Induced autoimmunity to heat shock proteins elicits glaucomatous loss of retinal ganglion cell neurons via activated T-cell derived fas-ligand. J. Neurosci. 2008, 28(46):12085-12096. (PMID: 19005073).
64. Whitmore A., Libby R.T., John S.W. Glaucoma: thinking in new ways-a role for autonomous axonal self-destruction and other compartmentalised processes?. Prog. Retin. Eye Res. 2005, 24:639-662.
65. Xu P., Liu J., Sakaki-Yumoto M., Derynck R. TACE activation by MAPK-mediated regulation of cell surface dimerization and TIMP3 association. Sci. Signal. 2012, 5:222. (PMID: 22550340).
66. Yang Y., Jalal F.Y., Thompson J.F., Walker E.J., Candelario-Jalil E., Li L., Reichard R.R., Ben C., Sang Q.X., Cunningham L.A., Rosenberg G.A. Tissue inhibitor of metalloproteinases-3 mediates the death of immature oligodendrocytes via TNFα/TACE in focal cerebral ischemia in mice. J. Neuroinflammation 2011, 8(108). (PMID: 21871134).
67. Zarubin T., Han J. Activation and signaling of the p38 MAP kinase pathway. Cell Res. 2005, 15(1):11-18. (PMID: 15686620).